Medical News

RSS

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Cambridge Heart, Inc., today announced the first patient enrollments in the MTWA-CAD study (Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients with Known or Suspected Coronary Artery Disease).

7 Jul 2010

MJFF teams up with EHE International to raise awareness of Parkinson's disease

The Michael J. Fox Foundation for Parkinson's Research is teaming up with EHE International to raise awareness of the fight against Parkinson's disease. For the month of July, EHE International has kindly donated a 115-square-foot window space at 10 Rockefeller Plaza to showcase the many ways ordinary citizens can support the Foundation through its grassroots fundraising arm, Team Fox.

7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Lancet study series examines health in the Gaza Strip

Reuters reports on a series of studies published Friday in the Lancet, which examine the health of populations living in the Gaza Strip. The studies, which examined the effects of the violence on the region, conclude that Israel's blockade of the territory could "cause long-term damage to Palestinians' health, with many children at risk of stunted growth or malnutrition."

7 Jul 2010

Cymetrix announces expanded partnership with Torrance Memorial Medical Center

Cymetrix, a leader in providing hospitals and healthcare networks with revenue cycle management solutions, today announced an expanded partnership with Torrance Memorial Medical Center to provide self-pay accounts receivable management services. Cymetrix's outstanding performance, and its ability to help the medical center increase its payments from managed care organizations during an earlier contract, contributed to Torrance Memorial's decision to expand its partnership.

7 Jul 2010

Research findings could help save lives from sick sinus syndrome

The pioneering research, using detailed computer models, could help save lives through preventative treatment of those most at risk from a form of heart rhythm disorder called sick sinus syndrome.

From The University of Manchester 7 Jul 2010

Washington Post examines birth simulator for health worker training in developing world

A new device which simulates childbirth on a real woman could help train health workers to deliver babies and deal with complications, according to the Washington Post, which adds that the $100 low-tech "frontpack" is called "'MamaNatalie,' a name that plays on 'natalis,' which means 'pertaining to birth' in Latin."

7 Jul 2010

PhyloTech closes $1.2M Seed financing round

PhyloTech, Inc., announced today it closed a $1.2 M Seed financing round in June. The Company provides analysis of over 50,000 bacterial and archaeal taxa in samples from any source to solve problems in human health, environmental damages assessment, bioremediation, recreational water quality, drinking water and food safety, and an array of other applications.

7 Jul 2010

WHO H1N1 response probe's second meeting highlights divergent views

The independent team of health experts responsible for reviewing the WHO's response to H1N1 (swine flu) wrapped up a second round of public hearings on Friday, "during which members heard testimony from widely divergent groups, from health officials to some of its most public critics," CIDRAP News reports.

7 Jul 2010

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Caraco Pharmaceutical Laboratories, Ltd. has started shipping azelastine ophthalmic solution, 0.05%. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA).

7 Jul 2010

FDA approves Glassia for treating Alpha 1 deficiency

Kamada, today announced that the United States Food and Drug Administration has approved Glassia (Alpha 1 Proteinase inhibitor, also known as Alpha-1-Antitrypsin) for the treatment of Alpha 1 deficiency. GlassiaM is now the first and only liquid Alpha- 1-Proteinase Inhibitor worldwide available liquid, ready to use, Alpha- 1-Proteinase Inhibitor on the market.

7 Jul 2010

Consumer groups: Force insurers to provide more details justifying price increases

Kaiser Health News staff writer Julie Appleby reports on the continuing evolution of the new health overhaul's implementation rules: "Consumer advocates this week pushed for tough rules on how much information insurers must provide to justify premium increases, a step required by the new health overhaul law" (Appleby, 7/6).

7 Jul 2010

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

"The Democratic chairman of the House Veterans Affairs Committee lambasted the Obama administration over its handling of an incident at a St. Louis VA center in which more than 1,800 veterans were told they may have been exposed to HIV. ... The Department of Veterans Affairs last month sent a letter to 1,812 patients informing them that could have been exposed to HIV and other deadly viruses because of dental equipment that was insufficiently sterilized over a period of 13 months."

7 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Experts show the continuing global impact of Framingham Heart Study

Few medical investigations have had the impact of the Framingham Heart Study. This study, started in 1948, was designed as a cohort, observational study of cardiovascular disease, then recognized as a growing health threat but now has emerged as much more. The Framingham Heart study came to revolutionize thinking about cardiovascular disease, change the study of epidemiology, and even force the biostatistics community to develop multivariate analysis.

7 Jul 2010

US WorldMeds launches Revonto for malignant hyperthermia

US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Medical News

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

MJFF teams up with EHE International to raise awareness of Parkinson's disease

FDA approves IMT to improve vision in patients with end-stage AMD

Study finds additional targets for new therapies to treat advanced prostate cancer patients

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

Lancet study series examines health in the Gaza Strip

Cymetrix announces expanded partnership with Torrance Memorial Medical Center

Research findings could help save lives from sick sinus syndrome

Washington Post examines birth simulator for health worker training in developing world

PhyloTech closes $1.2M Seed financing round

WHO H1N1 response probe's second meeting highlights divergent views

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

FDA approves Glassia for treating Alpha 1 deficiency

Consumer groups: Force insurers to provide more details justifying price increases

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

Shire receives FDA approval of Daytrana for ADHD in adolescents

Experts show the continuing global impact of Framingham Heart Study

US WorldMeds launches Revonto for malignant hyperthermia

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News